Biomarker Core
生物标志物核心
基本信息
- 批准号:10409747
- 负责人:
- 金额:$ 40.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Algorithmic AnalysisAlzheimer&aposs DiseaseAlzheimer&aposs disease diagnosisAlzheimer’s disease biomarkerAmyloid beta-42Amyloid beta-ProteinBioinformaticsBiological AssayBiological MarkersBiologyBloodBlood CellsCardiovascular DiseasesCellsClinicalClinical ManagementCollectionCytometryDNADataData AnalysesData SetDatabasesDementiaDetectionDevelopmentDiabetes MellitusDiseaseEquipment and supply inventoriesFecesFibroblastsGene ExpressionGeneticGlial Fibrillary Acidic ProteinGoalsHumanImageImmuneIndividualInformation DisseminationLeadLightLiquid substanceMeasurementMeasuresMethodsMissionMolecularNerve DegenerationNeurodegenerative DisordersParkinson DiseaseParkinson&aposs DementiaParticipantPathologic ProcessesPeripheral Blood Mononuclear CellPhenotypePlasmaPopulations at RiskProcessProteomeProteomicsPublishingQuality ControlRNAReproducibilityResearchResearch PersonnelSamplingSensitivity and SpecificitySignal TransductionSkinSourceStandardizationT-Cell ReceptorTechnologyTimeTissuesTraining SupportWorkanalysis pipelinebasebioinformatics toolbiomarker performancedata managementdata sharingexperiencegenetic variantgut microbiomeimaging modalitymembermicrobiomemolecular markermultiple omicsneurofilamentneuropathologynext generationnovelnovel markernovel therapeuticspublic databasereceptor expressionresearch studyskin microbiomestool sampletau Proteinstau-1tissue biomarkerstooltranscriptometranscriptome sequencingtranscriptomicsweb portalwhole genome
项目摘要
1. SUMMARY (Biomarker Core)
Biomarkers have enormous value for the detection, management, and treatment of disease, but also for the
development of novel therapeutics. The utility of biomarkers is most evident in the management of
cardiovascular disease and diabetes, but biomarkers, especially predictive, easily obtainable ones, are still
largely absent with respect to neurodegenerative diseases. The best fluid biomarkers currently available for
Alzheimer’s disease (AD) include; Aβ, tau, and neurofilament in CSF, a biofluid which is difficult to collect in
healthy, at-risk populations or on a repeated basis. Other biomarkers for AD include imaging modalities which
are often very expensive or have low sensitivity and specificity at the individual level. The members of this core
have considerable experience in unbiased multi-omic screens and data analysis and, over the years, have
published numerous studies towards developing new biomarkers for neurodegenerative and other diseases.
Enabled by the current ADRC, the core leaders and collaborators have used biospecimens from Stanford
ADRC participants and generated extensive preliminary data with unbiased deep immune phenotyping,
proteomics, and transcriptomics of human CSF resident cells, and discovered novel Parkinson's disease (PD)
biomarkers. Based on this expertise, the mission of this Biomarker Core is to facilitate the discovery of novel
biomarkers for AD and PD, as well as new biology underlying the pathological processes that lead to dementia
in line with the core mission of the NAPA. This will be achieved by pursuing the collection of genetic and
molecular measurements from a broad source of tissues from ADRC participants; the processing and
dissemination of this information in useable formats through web portals and other means (i.e., “Deep
Phenotyping Database”); the analysis and bioinformatics integration of the collected information with clinical
and imaging data, as well as information from public databases; and the development and dissemination of
new data analysis algorithms and pipelines.
1.总结(生物标志物核心)
生物标志物对于疾病的检测、管理和治疗具有巨大的价值,而且对于
开发新的治疗方法。生物标志物的效用在以下管理中最为明显:
心血管疾病和糖尿病,但生物标志物,特别是预测,容易获得的,仍然是
在神经退行性疾病方面基本上不存在。目前最好的液体生物标志物可用于
阿尔茨海默病(AD)包括:CSF中的Aβ、tau和神经丝,CSF是一种难以在体内收集的生物流体。
健康的、有风险的人群或重复使用。AD的其他生物标志物包括成像方式,
通常非常昂贵或者在个体水平上具有低灵敏度和特异性。核心成员
在无偏见的多组学筛选和数据分析方面有相当丰富的经验,多年来,
发表了许多研究,旨在开发神经退行性疾病和其他疾病的新生物标志物。
在当前ADRC的支持下,核心领导者和合作者使用了来自斯坦福大学的生物标本
ADRC参与者,并产生了广泛的初步数据与公正的深度免疫表型,
蛋白质组学和人类CSF驻留细胞的转录组学,并发现了新的帕金森病(PD)
生物标志物。基于这种专业知识,该生物标志物核心的使命是促进发现新的
AD和PD的生物标志物,以及导致痴呆的病理过程的新生物学
符合国家适应行动方案的核心使命。这将通过收集基因和
来自ADRC参与者的广泛组织来源的分子测量;处理和
通过门户网站和其他手段以可用的格式传播该信息(即,“深
表型数据库”);收集的信息与临床
和成像数据,以及公共数据库中的信息;
新的数据分析算法和管道。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TONY WYSS-CORAY其他文献
TONY WYSS-CORAY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TONY WYSS-CORAY', 18)}}的其他基金
2023 Biology of Aging Gordon Research Conference and Gordon Research Seminar
2023年衰老生物学戈登研究会议暨戈登研究研讨会
- 批准号:
10675884 - 财政年份:2023
- 资助金额:
$ 40.06万 - 项目类别:
Targeting CD22 to Restore Brain Homeostasis in Alzheimer's Disease
靶向 CD22 恢复阿尔茨海默氏病的大脑稳态
- 批准号:
10234488 - 财政年份:2019
- 资助金额:
$ 40.06万 - 项目类别:
Microglial dysfunction in brain aging and Alzheimer's disease
大脑衰老和阿尔茨海默病中的小胶质细胞功能障碍
- 批准号:
9911972 - 财政年份:2019
- 资助金额:
$ 40.06万 - 项目类别: